Vergent Bioscience Stock

vergentbio.comHealthcare / BioTech & PharmaFounded: 2016

Vergent Bioscience is a biopharma research and development company that specializes in the identification and treatment of cancers and tumors. Vergent Bioscience partners with scientist and healthcare organizations with their minimally invasive, robotic assisted techniques to improve the visibility of a variety of tumors that at times, can be undetectable or difficult to find. Furthermore, Vergent Bioscience’s clinical technology can aid in removing tumor tissue fully.

Register for Details

For more details on financing and valuation for Vergent Bioscience, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Vergent Bioscience.

Register Today

Other companies like Vergent Bioscience in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Vergent Bioscience Secures $21.5 Million Series B Financing to Advance Clinical Development of Tumor-Targeted Fluorescent Imaging Agent VGT-309
Vergent Bioscience, a clinical-stage biotechnology company developing tumor-targeted imaging agents, today announced the close of a $21.5 million Series B financing.
Updated on: Sep 29, 2023